Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (ACRX) on May 31, 2022. The company is a Delaware corporation with its principal executive offices in Hayward, California. The filing reports two material events: the termination of a royalty monetization agreement and a notice of potential delisting from The Nasdaq Global Market due to non-compliance with minimum bid price requirements.
Key Financial Metrics
The filing does not provide standard revenue, profit, or cash flow metrics for a reporting period. However, it discloses specific balance sheet impacts related to the termination of a material agreement:
- Liability Extinguished: $84.6 million (recorded as of March 31, 2022).
- Termination Consideration Paid: $0.1 million.
- Net Equity Impact: Stockholders' equity will increase by $84.5 million.
- Pro Forma Equity: Had the termination been effective as of March 31, 2022, stockholders' equity would have been $46.2 million, reversing a reported deficit of $38.3 million.
Material Changes
Termination of Royalty Monetization: On May 31, 2022, AcelRx and SWK Funding, LLC agreed to terminate the Royalty Monetization agreement regarding European royalties for Zalviso. This eliminates the company's obligation to SWK. The accounting for this transaction will be reflected in the Form 10-Q for the period ended June 30, 2022.
Nasdaq Delisting Notice: The company failed to regain compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share for 10 consecutive business days within a 180-day cure period. On June 1, 2022, Nasdaq notified the company that its common stock is subject to delisting.
Outlook, Risks, and Management Commentary
Delisting Appeal: AcelRx has appealed Nasdaq's determination and intends to submit a plan to regain compliance, which may include a reverse stock split. The company is eligible to seek an additional 180-day compliance period if it meets other listing standards, though there is no assurance the request will be granted.
Risks: The primary risk is the potential delisting of the company's common stock from The Nasdaq Global Market if the appeal is denied or if the company fails to cure the deficiency during the additional compliance period.
Investor Verification Checklist
- Verify the final outcome of the Nasdaq delisting appeal and the status of the additional compliance period.
- Confirm the exact accounting treatment and timing of the $84.5 million equity increase in the upcoming Form 10-Q for the period ended June 30, 2022.
- Monitor the company's stock price to assess the likelihood of regaining the $1.00 minimum bid price requirement.
- Review the proposed reverse stock split plan (if submitted) for its impact on share count and liquidity.